Lilly says no higher offer for SGX

Eli Lilly says it won't be sweetening its offer for SGX Pharmaceuticals. The company says its bid of $3 a share, which had doubled the stock's value, was its best and final offer. Shareholders vote August 20. Report

Suggested Articles

Bluebird Bio CEO snares $24 million pay package as gene therapy advance
Biotech

Bluebird’s CAR-T follow-up shows promise in phase 1

Bluebird Bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.

by Amirah Al Idrus
Biotech

Cancer biotech Zentalis uncloaks with $85M

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

by Amirah Al Idrus
Merck
Biotech

Merck inks $2.7B ArQule deal, teeing up cancer race with Lilly

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

by Nick Paul Taylor